Описание
Статус выполнения
completedResults
Ход выполнения
Заболевания
Цели
This Phase IV, multicenter study will evaluate whether participants with Hemophilia A (PwHA) with or without inhibitors receiving emicizumab prophylaxis can safely undergo minor surgical procedures without additional prophylactic bypassing agents (BPA; for participants with inhibitors) or factor VIII (FVIII; for participants without inhibitors).
Организация, проводящая КИ
Genentech, Inc.
Фаза КИ
IV
Количество пациентов
14
Источник